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RESEARCH ARTICLE
Limitations of using feline coronavirus 
spike protein gene mutations to diagnose feline 
infectious peritonitis
Emily N. Barker1*, Angelica Stranieri2, Chris R. Helps1, Emily L. Porter1, Andrew D. Davidson3, Michael J. Day1, 
Toby Knowles1, Anja Kipar4,5 and Séverine Tasker1
Abstract 
Feline infectious peritonitis (FIP) is a fatal disease of cats, and a sequela of systemic feline coronavirus (FCoV) infec-
tion. Mutations in the viral spike (S) gene have been associated with FCoVs found in tissues from cats with FIP, but 
not FCoVs found in faeces from healthy cats, and are implicated in monocyte/macrophage tropism and systemic 
spread. This study was designed to determine whether S gene mutation analysis can reliably diagnose FIP. Cats were 
categorised as with FIP (n = 57) or without FIP (n = 45) based on gross post-mortem and histopathological exami-
nation including immunohistochemistry for FCoV antigen. RNA was purified from available tissue, fluid and faeces. 
Reverse-transcriptase quantitative-PCR (RT-qPCR) was performed on all samples using FCoV-specific primers, followed 
by sequencing of a section of the S gene on RT-qPCR positive samples. Samples were available from a total of 102 
cats. Tissue, fluid, and faecal samples from cats with FIP were more likely to be FCoV RT-qPCR-positive (90.4, 78.4 and 
64.6% respectively) than those from cats without FIP (7.8, 2.1 and 20% respectively). Identification of S gene mutated 
FCoVs as an additional step to the detection of FCoV alone, only moderately increased specificity for tissue samples 
(from 92.6 to 94.6%) but specificity was unchanged for fluid samples (97.9%) for FIP diagnosis; however, sensitivity was 
markedly decreased for tissue (from 89.8 to 80.9%) and fluid samples (from 78.4 to 60%) for FIP diagnosis. These find-
ings demonstrate that S gene mutation analysis in FCoVs does not substantially improve the ability to diagnose FIP as 
compared to detection of FCoV alone.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Feline coronavirus (FCoV) infection is ubiquitous in 
domestic cats, with up to 90% of cats within multicat 
households being infected [1, 2]. The majority of FCoV 
infections are asymptomatic or are associated with mild 
intestinal disease. However, an estimated 1 to 5% of 
infected cats develop feline infectious peritonitis (FIP) [3, 
4], characterised by the development of a variable com-
bination of pyogranulomatous polyserositis, vasculitis 
and granulomatous lesions in organs, and an extremely 
high mortality rate [5, 6]. Avirulent or self-limiting FCoV 
infection was believed to be confined to the intestines, 
but we now know that healthy FCoV-infected cats can 
have systemic FCoV infection, albeit with lower FCoV 
viral loads than cats with FIP [7–10].
There are two different serotypes of FCoV, both of 
which can cause FIP. Serotype 1 FCoVs are wholly feline 
viruses, whereas serotype 2 FCoVs have arisen from 
recombination events between serotype 1 FCoVs and 
canine coronavirus (CCoV), involving genes encoding the 
C-terminal section of the replicase complex, spike pro-
tein, non-structural accessory proteins 3a–c, and part of 
the envelope protein [11]. There is worldwide geographi-
cal variation in the relative distribution of serotype 1 and 
2, and co-infections can occur [12–17].
The “reference standard” for the definite diagnosis of FIP 
is the demonstration of FCoV antigen within histologi-
cal specimens of the lesions consistent with FIP, usually by 
immunohistochemistry (IHC) [5]. As IHC requires an inva-
sive sampling procedure, and has significant cost and time 
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implications, alternative diagnostic techniques have been 
investigated, such as detection of FCoV and characterisa-
tion of FCoV genomic sequences, using pyrosequencing, 
Sanger sequencing or sequence specific hydrolysis probes. 
Recent studies have identified mutations in the gene encod-
ing spike (S) protein of serotype 1 FCoVs that are implicated 
in monocyte/macrophage tropism [18]. Two amino acid 
substitutions, M1058L and/or S1060A corresponding to 
nucleotide mutations 23531A>T/C and 23537T>G respec-
tively in the S gene, together distinguished FCoVs found 
in the tissues of FIP cats from those found in the faeces of 
healthy cats without FIP in > 95% of cases. A subsequent 
study, which compared detection of FCoV by RT-qPCR 
alone to detection of FCoV by RT-qPCR combined with 
sequence analysis to confirm the presence of nucleotide 
mutations 23531A>T/C and 23537T>G, concluded that 
the addition of an assay for S gene mutation analysis did not 
alter the specificity of the FIP diagnosis, which was already 
100%, but did decrease the sensitivity from 9.4 to 6.3% for 
serum/plasma samples and from 72 to 64% for effusion 
samples [19]. However, we have shown that the nucleo-
tide mutations 23531A>T/C and 23537T>G are likely to 
be markers of systemic FCoV infection rather than FIP per 
se, being present in 91% of the FCoV-positive tissue sam-
ples from cats with FIP and 89% of the FCoV-positive tissue 
samples from cats without FIP [20].
The aim of this study was to analyse a larger number 
of tissue, fluid and faeces samples from the University 
of Bristol FIP Biobank to assess the usefulness of S gene 
mutation analysis in the diagnosis of FIP.
Materials and methods
See Figure 1 for the diagnostic pathway used in this study 
for sample selection.
Sample collection and storage
Post-mortem tissue samples, faeces/faecal swab and body 
cavity fluid, if present in excess volume, were collected 
from cats that were euthanized with suspected FIP or 
due to other systemic diseases or very rarely on behav-
ioural grounds. Some samples were included in earlier 
studies [20, 21]. Collection of cerebrospinal fluid (CSF), 
where possible, was performed immediately following 
euthanasia as part of a clinical training programme and 
was independent of presence of presenting neurological 
signs, which were not specifically evaluated. Where pos-
sible age and presenting signs were recorded.
Tissue samples were collected into RNAlater (Life 
Technologies) within 2  h of death, as per manufactur-
ers’ instructions, and stored at −80 °C pending molecu-
lar analysis. Further samples were collected into 10% 
neutral-buffered formalin for histological examination 
and IHC. The tissues collected comprised primarily mes-
enteric lymph nodes, liver, kidney, spleen and omentum, 
while other tissues (e.g. intestine, brain, lungs, pericar-
dium, pancreas or other lymph nodes) were included 
based on gross pathological findings or reported clinical 
signs. Body cavity fluid samples (e.g. ascitic fluid, pleural 
fluid, pericardial fluid, aqueous humour and CSF) were 
collected into plain or EDTA-anticoagulant blood tubes. 
Where immediate storage at −80  °C was not possible, 
Figure 1 Diagnostic pathway used. Asterisk: Cats for which no samples were collected into formalin or RNAlater were excluded from further 
analysis.
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fluid was combined with RNAlater (20% v/v) upon col-
lection and moved to long-term storage at −80 °C within 
24 h to 1 week. Faecal samples were stored immediately 
upon receipt at −80 °C until use.
Histological examination and immunohistochemistry 
for FCoV antigen
Formalin-fixed tissue samples were subjected to stand-
ard processing for histological examination. They were 
trimmed and routinely embedded in paraffin wax. Sec-
tions  (3–5  µm) were prepared and stained with haema-
toxylin–eosin, and, for the confirmation of FIP, subjected 
to IHC for FCoV antigen as previously described [22].
Disease category
For a cat to be assigned to the “with FIP” group, one or 
more tissues needed to have histopathological changes 
consistent with FIP, and the presence of FCoV antigen 
within lesional macrophages confirmed [22]. For a cat to 
be assigned to the “without FIP” group, gross and histo-
pathological changes consistent with FIP needed to be 
absent from all tissues collected, which had to include 
those associated with available ante-mortem clinical 
findings (e.g. eye if uveitis reported). Body cavity fluid 
and faecal samples were classified as “with FIP” or “with-
out FIP” on the basis of the classification of the cat from 
which they originated.
For cats for which FIP was considered as a differen-
tial diagnosis based on clinical history, but for which no 
changes supportive of FIP were present on histological 
examination and for which a definite alternative diagno-
sis was not achieved (e.g. for definitive diagnosis addi-
tional tissues should have been examined by histology), 
inclusion within either the FIP or without FIP groups 
could not be made; these cats were excluded from further 
analysis. Cats for which there were no samples collected 
into formalin or RNAlater were also excluded from fur-
ther analysis.
RNA extraction and RT‑qPCR
Total RNA was extracted from 20  mg of tissue with a 
NucleoSpin RNA II kit (Macherey–Nagel) using meth-
ods previously described [23]. Total RNA was extracted 
from 100 µL body cavity fluid or 10 mg of faeces or faecal 
swab using either the NucleoSpin RNA II kit or using an 
automated platform Chemagic 360 instrument (Perkin-
Elmer) in combination with Chemagic body fluids NA kit 
(Perkin-Elmer) eluted in 100 µL elution buffer.
Reverse transcription was performed using a MJ Mini 
Gradient Thermal Cycler and ImProm II Reverse Tran-
scriptase (Promega). Ten microlitre of total RNA were 
combined with ImProm II 5  ×  Reaction Buffer, 3  mM 
 MgCl2, dNTPs (0.5 mM each), random hexamers (25 ng/
μL) and ImProm II reverse transcriptase in a total volume 
of 20 μL. The following thermal profile was used; 20  °C 
for 5 min, 42 °C for 30 min, 70 °C for 15 min and 10 °C 
hold. The resulting 20 μL of cDNA was added to 30 μL 
of RNase-free water and stored at −20  °C. Randomly 
selected samples were checked for inhibition of the RT 
reaction using an RNA internal amplification control. No 
inhibition was detected (results not shown).
Quantitative PCR was performed using: 2  ×  GoTaq 
Master Mix (Promega), 200  nM forward and reverse 
primers (P009/P010), 25 nM TaqMan probe (P1), 2.5 mM 
MgCl2 and 5  μL cDNA in a total volume of 25  μL; the 
following thermal profile: 95  °C for 2 min and 40 cycles 
of 95 °C for 15 s, 55 °C for 15 s and 72 °C for 15 s; in an 
Agilent Mx3005P qPCR System (Agilent Technologies). 
The primers and probe were synthesized by Metabion 
(Metabion International) and were described previously 
[24]. Fluorescence was detected at 520  nm during the 
extension phase. FCoV cDNA was used as a positive con-
trol and RNase-free water as a negative control. Relative 
FCoV copy number per reaction was calculated for posi-
tive samples, as previously described [20].
S gene mutation analysis by pyrosequencing
Samples that were positive by FCoV RT-qPCR then 
underwent conventional PCR to amplify a 153 base-pair 
(bp) DNA fragment encompassing amino acid positions 
M1058L and S1060A in the S protein gene of serotype 1 
FCoV, and subsequent pyrosequencing of the amplicon. 
Amplification and sequencing primers (Table  1) were 
designed using a combination of PyroMark assay design 
software (Qiagen), Primer3 [25] and MFold [26], and 
were made by Eurofins (MWG Operon) or Metabion. 
Degeneracies were added to the primers, and the loca-
tion of the primers optimised, based upon a sequence 
alignment comprised of all available serotype 1 FCoV 
genomes (data not shown). Briefly, PCR was performed 
using: 2  ×  GoTaq Master Mix (Promega), 200  nM for-
ward and biotinylated reverse primers (F614/R766), 5 μL 
cDNA in a total volume of 25 μL; the following thermal 
profile: 95 °C for 2 min, 40 cycles of 95 °C for 15 s, 52 °C 
for 20 s and 72 °C for 20 s, before being held at 10 °C; in 
a MJ Mini Gradient Thermal Cycler. Samples that failed 
to produce definitive sequence data were pyrosequenced 
following repeat amplification using the same PCR proto-
col with 50 cycles of amplification.
Pyrosequencing was performed as previously described 
[20] using either PyroMark Q24 (Qiagen) or Pyromark Q96 
(Qiagen) platforms. The dispensation order of the nucleo-
tides was defined as; CGCTCATG for nucleotide position 
23531 and CGACTGC for nucleotide position 23537.
All samples sequenced were genotyped at the nucleo-
tide position 23531. All samples wild-type (i.e. adenine) 
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at nucleotide position 23531, and selected mutated sam-
ples, were subjected to sequencing at nucleotide position 
23537. Sequencing results were classified as non-mutated 
FCoV or mutated FCoV on the basis of absence or pres-
ence, respectively, of nucleotide mutations 23531A>T/C 
(M1058L) and 23537T>G (S1060A).
S gene mutation analysis by Sanger sequencing
Samples that failed to produce definitive pyrosequenc-
ing data were subjected to agarose gel (1% w/v) electro-
phoresis, using ethidium bromide stain, with EasyLadder 
I (50 ng/band; Bioline, London, UK) and analysed using 
a GelDoc-It® Imaging System (UVP LLC, Cambridge, 
UK) to confirm that a single amplicon of the correct 
size (153  bp) had been produced using primers F614/
R766 (PCR as described above). Samples that produced 
a 153  bp amplicon were subjected to Sanger sequenc-
ing. Sequencing was performed using non-biotinylated 
amplification primers in a standard protocol (DNA 
Sequencing and Services, http://www.dnaseq.co.uk).
Amplification of serotype 2 FCoV cDNA
Samples that were positive by FCoV RT-qPCR, with a 
threshold cycle  ≥  36 (relative copy number  ≤  15), but 
that did not generate a 153  bp amplicon using prim-
ers F614/R766 were subjected to PCR to determine the 
presence of serotype 2 FCoVs. Primers were designed 
to amplify a  ≈  1820  bp fragment encompassing the S1 
region of the S protein gene of serotype 2 FCoVs, as pre-
viously described [27]. Briefly, PCR was performed using: 
2 × GoTaq Master Mix (Promega), 400 nM forward and 
reverse primers (FCoV S2 F1/FCoV S2 R3), 5  μL cDNA 
in a total volume of 25 μL; the following thermal profile: 
95 °C for 2 min, 45 cycles of 95 °C for 15 s, 55 °C for 20 s 
and 72 °C for 2 min, followed by 72 °C for 5 min before 
being held at 10  °C; in an Agilent Thermal Cycler (Agi-
lent Technologies). Positive and negative PCR controls 
were included in each reaction. Reaction products were 
separated by agarose gel electrophoresis to confirm that 
a single amplicon of the correct size was produced. One 
reaction product from each cat was subjected to a stand-
ard Sanger sequencing protocol using the amplification 
primers as sequencing primers.
Statistical analysis
Data [comprising: cat identification number; age; diag-
nosis (with FIP vs without FIP); sample type (tissue, 
fluid and faeces) and specific organ/body cavity of origin 
where applicable; histopathology result (absence vs. pres-
ence of changes consistent with FIP); IHC result (absence 
vs. presence of FCoV antigen in lesions); FCoV RT-qPCR 
result; relative FCoV copy number; S protein mutation 
analysis result (non-mutated vs mutated vs serotype 2 vs. 
failed)] were entered into a database (Excel 2008, Micro-
soft; Additional file 1) and exported into IBM SPSS Statis-
tics software (version 23.0). Continuous variables within 
the data sets were evaluated for normal distribution using 
the Kolmogorov–Smirnov test. Non-normally distrib-
uted data were described as median and range (minimum 
and maximum values). Population proportions were 
compared using Chi squared test. Data evaluating FCoV 
relative copy numbers in tissue and faecal samples from 
cats with and without FIP were analysed using a multi-
level modelling approach (MLwiN v3) [28] to account for 
the repeated measures within cats. An alternative, simpli-
fied analysis was also employed in which non-parametric 
Mann–Whitney U tests were used to test for differences 
between cats on the individual measurements. The con-
clusions drawn from both analyses were in full agreement 
(data not shown), so the simpler Mann–Whitney U test 
analysis is presented here. Relative copy numbers were 
compared between the cats with FIP and cats without 
FIP for different sample types (tissue, fluid and faeces). 
Significance was assigned at a level of p < 0.05.
To determine the usefulness of a combined “FCoV RT-
qPCR and sequencing result” in the diagnosis of FIP: a 
sample was considered to have a positive result if a FCoV 
RT-qPCR-positive result was followed by detection of 
Table 1 Primer and probe sequences used in this study
qPCR: quantitative polymerase chain reaction, FCoV: feline coronavirus, FAM: fluorescein amidite, BHQ1: black hole quencher-1, BIO: biotin.
Name Use Sequence (5′–3′)
P009 qPCR forward primer AGCAACTACTGCCACRGGAT
P010 qPCR reverse primer GGAAGGTTCATCTCCCCAGT
TaqMan-P1 FCoV qPCR fluorescent probe FAM-AATGGCCACACAGGGACAACGC-BHQ1
F614 Forward pyrosequencing primer GCHCARTATTAYAATGGCATAATGG
R766 Biotinylated reverse pyrosequencing primer BIO-AAGYCTRGCYTGYACTTGCAT
S680 M1058L pyrosequencing primer ACAGCCTCDTTAATAGGVGGTATG
S693A S1060A pyrosequencing primer TAGGRGGTATGGCYWTGG
FCoV S2 F1 Forward FCoV type 2 spike gene fragment amplification primer TCTGCTGCCATCAAAATCAC
FCoV S2 R3 Reverse FCoV type 2 spike gene fragment amplification primer CGATGTGTAAGCAATTGTCCA
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mutated FCoV, either alone or mixed with non-mutated 
FCoVs; and a sample was considered to have a negative 
result if a FCoV RT-qPCR-negative result was obtained or 
a FCoV RT-qPCR-positive result was obtained followed 
by either detection of non-mutated FCoV or a failure to 
sequence the target sequence. Sensitivity was defined 
as the number of the samples from cats with FIP that 
were deemed positive based on the method under test 
(e.g. IHC, RT-qPCR, or combined RT-qPCR and S gene 
sequencing) out of the total number of samples from cats 
with FIP. Specificity was defined as the number of sam-
ples from cats without FIP that were deemed negative 
based on the method under test out of the total number 
of samples from cats without FIP. Accuracy was defined 
as the number of samples from cats with FIP that were 
deemed positive combined with the number of samples 
from cats without FIP that were deemed negative based 
on the method under test out of the total number of sam-
ples available.
Results
Samples were available from 127 cats (Figure 2); for 102 
of these, a definitive diagnosis was achieved (full details of 
the samples and results—Additional file 1): 57 cats with 
FIP; and 45 cats without FIP. Of the 25 cats excluded, five 
had no tissue samples collected into formalin, six had no 
tissue samples collected into RNAlater; and 14 only had 
limited tissue samples collected into formalin such that 
FIP could not be definitively diagnosed or excluded. Of 
the cats without FIP the reason for euthanasia and post-
mortem diagnosis comprised: neoplasia in 16; inflamma-
tory/infectious (not FIP) disease in 15; metabolic disease 
in four; cardiac in 1; immune-mediated in 2; miscellane-
ous in 6; and on behavioural grounds in 1.
Of the cats with FIP, the median age at euthanasia was 
9 months (range 2–144 months; 8 cats had indeterminate 
age). Of the cats without FIP median age at euthanasia 
was 96 months (range 4–180 months; two cats had inde-
terminate age). Cats without FIP were significantly older 
than cats with FIP (U = 207, p ≤ 0.001). When available, 
1–10 tissue samples (median 5 samples per cat) and/or 1 
to 4 fluid samples (median 1 sample per cat) were exam-
ined per cat. See Table 2 for origin of samples and sum-
mary of RT-qPCR results.
Of the 320 FCoV RT-qPCR-positive samples subjected 
to S gene mutation analysis 272 (85.0%) were success-
fully pyrosequenced (n =  89 at nucleotide 23531 alone, 
for M1058L; n  =  183 at nucleotides 23531 and 23537, 
for M1058L and S1060A), 21 (6.6%) required Sanger 
sequencing, and 27 (8.4%) failed target gene sequencing. 
For the outcome of S gene analysis of FCoV RT-qPCR-
positive samples see Table  3 (individual results can be 
found in Additional file 1).
Tissue sample analysis
Tissues from cats with FIP were more likely to be FCoV 
RT-qPCR-positive than tissues from cats without FIP (see 
Table  2; 90.4% (235/260) vs. 7.7% (20/258); χ2  =  353.8, 
p ≤ 0.001), and with a greater relative FCoV copy number 
(median 8.3 × 103 vs. 25; U = 2161.5, p ≤ 0.001).
Cats with FIP
Immunohistochemistry data were available for 224 of 
the 260 tissue samples, histopathological data alone were 
available for one further tissue sample and no histopatho-
logical data were available for 35 tissue samples from cats 
with FIP. Of the 57 cats with FIP, 56 (98.2%) had at least 
one tissue sample that was FCoV RT-qPCR-positive. One 
cat (#74) with severe pyogranulomatous lymphadenitis 
and pleuritis in association with FCoV antigen in intral-
esional macrophages, consistent with FIP, tested nega-
tive for FCoV by RT-qPCRs on all tissues. However, the 
use of alternative PCR primers detected FCoV in three 
of the four tissue samples available for analysis, whilst 
sequencing revealed mutations at the RT-qPCR primers 
(P009; P010) and probe (P1) binding sites. Four other tis-
sue samples from three cats (#61, #94, and #96) that had 
histopathological changes consistent with FIP, and were 
positive for FCoV antigen by IHC, but negative for FCoV 
by RT-qPCR, had limited, focal changes as confirmed by 
the histological examination. Tissues with histopatho-
logical changes (incl. IHC) consistent with FIP were 
more likely (χ2 = 10.9, p ≤ 0.001) to be FCoV RT-qPCR-
positive (132/139) than those without (69/85), and 
with a greater relative FCoV copy number (U = 2472.5, 
p ≤ 0.001; Table 4).
S gene mutation analysis was performed on 222 of the 
235 FCoV RT-qPCR-positive samples, of which 16 (7.1%) 
failed target gene sequencing. Four of the 16 samples 
that failed target gene sequencing were collected from 
two cats (#45 and #127) for which analysis of other tissue 
samples indicated the presence of mutated virus. These 
four samples had very low relative FCoV copy numbers 
(relative FCoV copy number ≤  19; see Table  3). Twelve 
of the 16 samples that failed sequencing were from five 
cats (#82, #92, #145, #146, and #147), all tissues had rela-
tive FCoV copy numbers (≥  41; see Table  3) that were 
expected to be successful at sequencing; additional PCRs 
of these samples revealed the presence of serotype 2 
FCoV. Only one of these cats (#92) had evidence of a non-
mutated, serotype 1 FCoV in another tissue sample. All 
of the cats found to have serotype 2 FCoVs were either 
resident in Greece (#145, #146, and #147), were imported 
to the UK from Greece (#82), or were suspected of hav-
ing been in contact with a cat imported to the UK from 
Greece that was euthanased with suspected FIP (#92). 
The origin of the remainder of the cats contained within 
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the Bristol FIP Biobank, where known, was the UK. Four 
tissue samples from three cats (#92, #97 and #103) had 
non-mutated FCoVs present in mesenteric lymph node 
(n  =  2), liver (n  =  1) and/or spleen (n  =  1): one cat 
(#97) had mutated FCoV in another tissue sample; one 
cat (#103) had both mutated and non-mutated FCoVs 
Figure 2 Distribution of samples available for analysis in the Bristol FIP Biobank.
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detected in other tissues; and one cat (#92) had sero-
type 2 FCoV in another tissue sample. Ten tissue samples 
from three cats (#43, #70 and #103) had sequence data 
consistent with the presence of both non-mutated and 
mutated (nucleotide 23531A>T/C) FCoVs, these com-
prised mesenteric lymph node (n  =  1), liver (n  =  3), 
omentum (n = 2), spleen (n = 2), lung (n = 1) and kidney 
(n = 1): one cat (#103) had non-mutated FCoV sequence 
in another tissue sample; and one cat (#43) had mutated 
FCoVs detected in other tissues. Two tissue samples 
from one cat (#79) had sequence data consistent with 
the presence of either non-mutated and double-mutated 
(nucleotides 23531A>T and 23537T>G in the same sam-
ple) FCoVs or both types of mutated FCoVs; these com-
prised omentum and spleen (n  =  2), which also had 
mutated FCoV detected in another tissue. These mixed 
FCoVs were not further characterised (i.e. as double or 
single mutants). Only mutated FCoVs were detected in 
190 samples: 186 with the M1058L mutation (nucleo-
tide 23531A>T n =  151; nucleotide 23531A>C n =  31; 
mixed, nucleotides 23531A>T and 23531A>C n = 4); and 
four with the S1060A mutation. In five of the cats (8.8%; 
#37, #43, #70, #100, and #101) different mutations were 
detected in different tissues.
Cats without FIP
Of the 45 cats without FIP, 12 (26.7%) had at least one tis-
sue positive for FCoV by RT-qPCR; IHC was negative for 
11 of these 12 cats, and not available for the 12th cat (#80, 
unstable diabetic, no histopathological findings sugges-
tive of FIP). Histopathological and IHC data were avail-
able for 181 of the 258 tissue samples, histopathological 
data alone were available for 77 further tissue samples. 
For all cats without FIP, histopathological examination 
did not find changes suggestive of FIP and all were IHC-
negative. Of those samples with available IHC 10.5 per-
cent were FCoV RT-qPCR-positive (see Table 4). Of the 
FCoV RT-qPCR-positive samples, three (15.8%) failed 
S gene mutation analysis and were collected from three 
cats (cats #80, #91 and #141); all had very low relative 
FCoV copy numbers (≤ 11; see Table 3).
Two tissue samples had non-mutated FCoVs present; 
these comprised colon and brain from one cat (#56, 
pyothorax and pyogranulomatous bronchopneumonia), 
Table 2 Origin of samples, RT-qPCR results and threshold cycle values
a All but one sample was obtained from the cerebellomedullary cistern, one sample was collected from the lumbar subarachnoid space.
Sample source Number of samples analysed 
by RT‑qPCR
RT‑qPCR positive result 
(%)
Threshold cycle for positive samples—median; 
range (relative copy number—median; range)
Cats with FIP
 Tissue 260 235 (90.4) 26.2; 12.4 to 39.7 (1.1 × 104; 1.2 × 108 to 1.2)
 Fluid 51 40 (78.4) 31.2; 19.4 to 38.5 (373; 1.1 × 106 to 2.7)
  Body cavity fluid 35 32 (91.4) 30.9; 19.4 to 38.5 (457; 1.2 × 108 to 1.2)
   Abdominal 23 21 (91.3) 30.8; 22.2 to 38.5 (488; 1.6 × 105 to 2.7)
   Pleural 9 9 (100.0) 29.6; 19.4 to 35.0 (1.1 × 10−3 1.2 × 108 to 29)
   Pericardial 2 1 (50.0) 38.5 (2.7)
   Unrecorded 1 1 (100.0) 37.0 (7.5)
  CSF 14a 7 (50.0) 34.8; 27.9 to 36.5 (33; 3.4 × 103 to 11)
  Aqueous humour 2 1 (50.0) 33.7 (6.9)
 Faeces 48 31 (64.6) 30.9; 15.8 to 39.7 (457; 1.2 × 107 to 1.2)
  Whole faeces 42 28 (66.7) 31.0; 15.8 to 37.7 (427; 1.2 × 107 to 4.7)
  Faecal swab 6 3 (50.0) 30.5; 30.5 to 39.7 (598; 598 to 1.2)
Cats without FIP
 Tissue 258 20 (7.8) 36.2; 26.4 to 38.5 (12.9; 9.4 × 103 to 2.7)
 Fluid 47 1 (2.1) 36.4 (11)
  Body cavity 28 1 (3.6) 36.4 (11)
   Abdominal 13 1 (7.8) 36.4 (11)
   Pleural 12 0
   Pericardial 3 0
  CSF 19 0
 Faeces 35 7 (20.0)
  Whole faeces 33 7 (20.0) 33.6; 25.7 to 38.6 (74; 1.5 × 104 to 2.6)
  Faecal swab 2 0 33.6; 25.7 to 38.6 (74; 1.5 × 104 to 2.6)
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which also had mutated FCoV in the liver. One sample 
(colon) from one cat (#63, central nervous system (CNS) 
astrocytoma) had sequence data consistent with the pres-
ence of both non-mutated and mutated (M1058L) FCoVs; 
no other tissues were FCoV RT-qPCR-positive. Only 
mutated FCoVs were detected in 14 samples, all of which 
had the M1058L mutation (nucleotide 23531A>T n = 7; 
nucleotide 23531A>C n = 7; none mixed).
Table 3 Outcome of target gene sequencing of RT-qPCR FCoV-positive samples
a Sequencing was not performed on 13 FCoV RT-qPCR positive tissue samples from FIP cats as no corresponding tissue in formalin were available for analysis.
b One FCoV RT-qPCR positive fluid sample was lost from analysis.
Sample source (number of RT‑
qPCR positive samples)
Outcome of target gene 
sequencing
Sequencing result (number of samples; median, and range, relative copy num‑
ber per reaction)
Cats with FIP
 Tissue (n = 222)a Success (n = 206) Non-mutated FCoVs (n = 4; 337, 2.6 × 105 to 5.4)
Mixed non-mutated and mutated FCoVs (n = 12; 1.1 × 103, 2.3 × 106 to 33)
M1058L (n = 10; 731, 4.4 × 105 to 33)
Double-mutated FCoVs (M1058L and S1060A) or mixed mutated FCoVs (n = 2; 
2.3 × 106 and 7.6 × 104)
Mutated FCoVs (n = 190; 1.3 × 104, 1.2 × 108 to 1.2)
M1058L (n = 186; 1.4 × 104, 1.2 × 108 to 1.2)
S1060A (n = 4; 1.8 × 104, 9.0 × 106 to 4.2 × 103)
Failure (n = 16) Low copy number (n = 4; 6.2, 19 to 4.1)
Presence of serotype 2 FCoVs (n = 12; 8.3 × 103, 2.5 × 107 to 41)
 Fluid (n = 39)b Success (n = 34) Non-mutated FCoVs (n = 4; 190, 1.3 × 103 to 41)
Mixed non-mutated and mutated (M1058L) FCoVs (n = 4; 15, 1.1 × 103 to 5.8)
Mutated FCoVs (n = 26; 457, 1.1 × 106 to 2.7)
M1058L (n = 25; 457, 1.1 × 106 to 2.7)
S1060A (n = 1; 3.2 × 103)
Failure (n = 5) Low copy number (n = 1; 2.7)
Presence of serotype 2 FCoVs (n = 4; 639, 2.0 × 104 to 27)
 Faeces (n = 31) Success (n = 29) Non-mutated FCoVs (n = 13; 1.1 × 105, 1.2 × 107 to 285)
Mixed non-mutated and mutated (M1058L) FCoVs (n = 2; 1.9 × 104 and 91)
Mutated (M1058L) FCoVs (n = 14; 63, 1.7 × 104 to 1.2)
Failure (n = 2) Presence of serotype 2 FCoVs (n = 2; 178 and 27)
Cats without FIP
 Tissue (n = 20) Success (n = 17) Non-mutated FCoVs (n = 2; 2.1 × 103 and 5.0)
Mixed non-mutated and mutated (M1058L) FCoVs (n = 1; 2.7)
Mutated (M1058L) FCoVs (n = 14; 63, 9.4 × 103 to 4.7)
Failure (n = 3) Low copy number (n = 3; 5.0, 11 to 4.7)
 Fluid (n = 1) Success (n = 1) Mutated (M1058L) FCoVs (n = 1; 11)
 Faeces (n = 7) Success (n = 6) Non-mutated FCoVs (n = 6; 330, 1.5 × 104 to 19)
Failure (n = 1) Low copy number (n = 1; 2.6)
Table 4 Results of FCoV antigen immunohistochemistry and FCoV RT-qPCR for tissue from cats with FIP and cats without 
FIP
a This includes 11 tissue samples with histopathological changes consistent with FIP, from cats definitively diagnosed with FIP based on analysis of additional tissue, 
but for which immunohistochemistry was negative (10 were positive for FCoV by RT-qPCR).
Tissue source RT‑qPCR Immunohistochemistry Total
Negativea Positive
Cats with FIP
Negative 16 7 23
Positive (relative copy number: median, range) 69 (1.2 × 103, 1.4 × 107 to 1.6) 132 (4.9 × 104, 1.2 × 108 to 1.2) 201
Total 85 139 224
Cats without FIP
Negative 162 0 162
Positive (relative copy number: median, range) 19 (16, 9.4 × 103 to 2.7) 0 19
Total 181 0 181
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Body cavity fluid samples
Fluid from cats with FIP was more likely (χ2  =  58.5, 
p ≤ 0.001) to be FCoV-positive (n = 40/51) compared to 
fluid from cats without FIP (n =  1/47). There were too 
few positive samples in the cats without FIP (n =  1) to 
compare copy numbers.
Cats with FIP
In one cat (#94) CSF was collected from both lumbar and 
cisternal sites, and was FCoV RT-qPCR-positive for the 
cisternal sample (relative FCoV copy number 104) and 
negative for the lumbar sample. Brain or spinal cord from 
this cat was not available for histological examination.
One FCoV RT-qPCR-positive sample (#100, pleural 
fluid) was lost from further analysis. Of the remaining 
FCoV RT-qPCR-positive samples five (12.8%) failed tar-
get gene sequencing. One of these samples (#98, peri-
cardial fluid), collected from a cat with mutated FCoV 
detected in tissue samples, had a very low relative FCoV 
copy number (see Table  3). Four were abdominal fluids 
from four cats (#82, #145, #146 and #147) that had rela-
tive FCoV copy numbers (≥  27; see Table  3) that were 
expected to be successful for sequencing; further analysis 
revealed the presence of serotype 2 FCoV. These four cats 
also had serotype 2 FCoV detected in tissue samples.
Four fluid samples had non-mutated FCoVs detected; 
these comprised abdominal fluid (n  =  3) and pleural 
fluid (n = 1) from three cats (#55, #70 and #93); two of 
which had mutated FCoVs in tissue samples (#55 and 
#93), and one of which had both non-mutated and mixed 
mutated FCoVs in tissue samples (#70). Four samples had 
sequence data consistent with the presence of both non-
mutated and mutated FCoVs; these fluids from three cats 
(#37, #79 and #103) were of abdominal (n =  1), pleural 
(n = 2), and unknown origin (n = 1); all cats had mutated 
FCoVs in tissue samples. Mutated FCoVs were detected 
in 26 samples; 25 with the M1058L mutation (nucleotide 
23531A>T n = 21; nucleotide 23531A>C n = 4); one with 
the S1060A mutation.
Cats without FIP
Only one sample of abdominal fluid from a cat (#125) 
with severe interstitial pneumonia was found to be FCoV 
RT-qPCR-positive, at a low level (relative FCoV copy 
number 11.3; see Table 3); sequencing revealed mutated 
(nucleotide 23531A>C) FCoV. Cytological analysis of this 
sample was not performed. This cat also had a low rela-
tive FCoV copy number (4.7) in a sample of lung tissue, 
which had the same S gene mutation.
Faecal samples
Faeces from cats with FIP was more likely (χ2  =  16.2, 
p ≤  0.001) to be FCoV RT-qPCR-positive (31/48) com-
pared to cats without FIP (7/35), but with no difference 
in relative copy number (U = 76, p = 0.221; FIP, median 
457.6, range 1.2 to 1.1 × 107; non-FIP, median 74.2, range 
2.6 to 1.5 × 104).
Cats with FIP
PCRs of the two samples that failed sequencing (#82 and 
#145) revealed the presence of serotype 2 FCoV. Both of 
these cats also had serotype 2 FCoV detected in tissue 
and fluid samples.
Cats without FIP
The sample for which sequencing (#115) failed had a very 
low relative FCoV copy number (2.6; see Table 3).
Sensitivity, specificity and accuracy
For sensitivity, specificity and accuracy of identification 
of FCoV by RT-qPCR alone or RT-qPCR in combination 
with subsequent detection of serotype 1 mutated FCoVs 
in the diagnosis of FIP see Table 5. There was no signifi-
cant difference between cats with FIP and cats without 
Table 5 Sensitivity, specificity and accuracy of diagnosis of FIP using molecular diagnostics
The reference-standard for diagnosis of FIP was considered identification of FCoV antigen by immunohistochemistry in at least one tissue in association with 
appropriate histopathological changes, and cats were considered “without FIP” where FIP was excluded as a diagnosis.
a As some positive samples without histopathological data were not subjected to sequencing, only those samples with histopathological data available were 
included in these calculations.
b RT-qPCR in combination with spike protein sequence characterisation FCoV.
c One sample lost from analysis.
Basis of diagnosis Tissuea Fluid Faeces
Sensitivity % (n = positive/total) RT-qPCR alone 89.8 (n = 202/225) 78.4 (n = 40/51) 64.6 (n = 31/48)
Combination  testingb 80.9 (n = 182/225) 60 (n = 30/50)c 33.3 (n = 16/48)
Specificity % (n = negative/total) RT-qPCR alone 92.6 (n = 239/258) 97.9 (n = 46/47) 80 (n = 28/35)
Combination  testingb 94.6 (n = 244/258) 97.9 (n = 46/47) 100 (n = 35/35)
Accuracy % (n = true result/total) RT-qPCR alone 91.3 (n = 441/483) 87.8 (n = 86/98) 71.1 (n = 59/83)
Combination  testingb 88.2 (n = 426/483) 78.4 (n = 76/97) 61.4 (n = 41/83)
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FIP for the proportion of mutated FCoVs detected in 
FCoV RT-qPCR-positive tissue and fluid samples (76.2% 
vs. 88.9%); χ2 = 2.96, p = 0.086).
Discussion
In total, 699 tissue, fluid and faeces samples were ana-
lysed from 102 cats, 57 with FIP and 45 without FIP. This 
is a marked increase in the number of samples analysed 
as compared to most previous studies [20, 21, 29, 30], and 
contains similar numbers of effusion samples to two pre-
vious studies [19, 31]. Some studies have examined the 
use of FCoV RT-PCR alone in the diagnosis of FIP using 
fluid samples [29, 31]. Other studies [19, 21] compared 
FCoV RT-PCR to FCoV RT-PCR in combination with 
characterisation of S gene mutations in the diagnosis of 
FIP using body cavity fluids, these derived similar sensi-
tivity (72 to 85% for FCoV RT-PCR alone and 60 to 64% 
for FCoV RT-PCR and S gene mutations characterisation) 
and specificity (100% for both FCoV RT-PCR alone and 
FCoV RT-PCR and S gene mutations characterisation) 
as obtained in this study (sensitivity 78.4% for FCoV RT-
PCR alone and 60% FCoV RT-PCR and S gene mutations 
characterisation; specificity 97.9 and 97.9% respectively).
As expected, in cats with histological changes consist-
ent with FIP, individual tissues without FIP lesions were 
more likely to be FCoV RT-qPCR-negative or have lower 
copy numbers than those tissues in which FIP lesions 
were present. Overall, however, FCoV RT-qPCR was 
more sensitive (89.7% vs. 62.1%; calculated from Table 4) 
than IHC at detecting FCoV in tissues from cats with FIP. 
Therefore, not surprisingly, to maximise the sensitiv-
ity of both IHC and RT-qPCR at detecting FCoV in cats 
with FIP, biopsies should be collected from tissues with 
imaging changes or gross visual changes consistent with 
granulomata, and from lesion sites, whenever possible. 
Distribution of granulomatous lesions within a tissue, 
and virus laden macrophages within a lesion, is not uni-
form, which could account for the failure to detect viral 
antigen in some FIP lesions, and the negative FCoV RT-
qPCR result in some cats in which the combined histo-
logical and IHC examination confirmed FIP. However, 
application of the calculated sensitivity to suspect FIP 
cases has to be viewed with caution, as not all samples 
included in the study were selected on the basis of clini-
cal signs and gross pathological changes. In contrast, 
10% of tissue samples from cats without FIP had a posi-
tive FCoV RT-qPCR result even though there were nei-
ther histological changes consistent with FIP nor was 
there evidence of viral antigen expression in tissue mac-
rophages by IHC, resulting in a specificity of 90% for 
FCoV RT-qPCR, as compared to 100% for the reference 
standard of IHC. Persistence of FCoV in both intestinal 
and extraintestinal tissue macrophages in the absence of 
disease has been reported in healthy cats experimentally 
infected with FCoV, albeit with authors reporting IHC 
to be a relatively insensitive method of FCoV detection 
compared with RT-qPCR [7].
Two previous studies on cerebrospinal fluid only eval-
uated samples collected from the cerebellomedullary 
cistern [29, 30]. One study evaluated the use of immu-
nocytochemistry for the diagnosis of FIP; when all sam-
ples were combined there was a sensitivity of 81% and a 
specificity of 85% [30]. The other study evaluated the use 
of RT-qPCR for the diagnosis of FIP, where the sensitivity 
was 42%, but specificity was 100 percent [29]. The results 
of the latter study are comparable with those of the cur-
rent study (sensitivity 50%; specificity 100%). However, 
the apparent effect of the site of cerebrospinal fluid col-
lection on diagnostic sensitivity of FCoV infection war-
rants further investigation. In cats with FIP there may be 
concern that some clinical signs could relate to increased 
intracranial pressure, where lumbar sampling could pro-
vide lower risk of herniation cf. cisternal sampling; how-
ever, FIP lesions rarely go beyond the leptomeninges of 
the brain stem (unpublished results).
Detection of FCoV by RT-qPCR in colonic tissue of 3 
cats without FIP was not surprising as enteric infection 
has been described in otherwise clinically healthy cats [7, 
8, 32]. These 3 cats were euthanized as a result of clini-
cal signs relating to pyothorax, brain tumour and nasal 
adenocarcinoma, had unremarkable histopathological 
examination and negative IHC of colonic tissue. In the 2 
of the 3 cats where faeces were available for testing there 
was no detectable viral shedding. In 1 cat the FCoV was 
non-mutated, another cat had mutated FCoV, and in the 
remaining cat mixed non-mutated and mutated FCoV 
was detected. Of note, the cat with pyothorax also had 
non-mutated virus detected at a low level in its brain, and 
mutated virus detected at low level in its liver, suggesting 
that it was viraemic at the time of death and that the virus 
persisted not only in the colon but also in extraintesti-
nal tissue macrophages [7]. If colonic tissue samples are 
excluded, all but one tissue sample from the non-FIP cats 
that were FCoV RT-qPCR-positive for which sequence 
data were available (n = 13) had mutated FCoV, confirm-
ing our previous findings that S gene mutations are a 
marker of systemic spread [20].
False-negative FCoV RT-qPCR results are possible, due 
to the high rate of FCoV genomic mutation, which could 
result in inefficient binding at the primer and/or probe 
sites. As only samples with FCoV RT-qPCR-positive 
results had pyrosequencing performed, FCoV RT-qPCR-
negative results were not confirmed. However, false neg-
ative RT-qPCR results are considered to be uncommon, 
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and were only detected in 1 of 57 cats with confirmed FIP 
in this study where at least one tissue from all the other 
cats were positive.
It is possible that the calculated relative FCoV copy 
numbers in this study are an overestimate of viral load. 
FCoV RT-qPCR assays amplify both cell-associated sub-
genomic mRNA, as well as cell-associated or virion-
associated genomic RNA, with relative abundance 
determined by the positioning of primers. As viral 
transcription starts at the 3′ end of the FCoV genome 
there are more subgenomic mRNAs containing viral 3′ 
sequence than those containing viral 5′ sequence, hence 
assays directed at the 5′ end of the genome (e.g. viral 
replicase complex genes) are less susceptible to viral 
load overestimation than those directed at the 3′ end of 
the genome (e.g. 7a/b accessory protein genes). The RT-
qPCR assay used in the present study targets the region 
spanning the membrane-nucleocapsid gene junction 
(nucleotides positions 26655–26826 of FCoV isolate 
FIPV 79–1146 DQ010921) [24]. Overestimation is less of 
an issue in the faecal samples, firstly as faeces has a high 
level of bacteria, and is thus rich in RNases that would 
degrade any RNA released from cells shed into the gut 
lumen, and secondly as the viral RNA is most likely to be 
present in its virion form, which does not contain sub-
genomic mRNA and is protected from RNase degrada-
tion by the viral envelope. Any cell-associated viral RNA 
is likely to be degraded due to cell death and the abun-
dant RNases. This study did not determine whether any 
faecally shed FCoV was infective; this is an important 
concept as faeces containing mutated FCoV theoretically 
has increased potential to cause FIP following faeco–
oral transmission, assuming the mutated virus can enter 
enterocytes and replicate. Previous studies have reported 
39–85% of FCoVs detected in tissues from cats with FIP 
had loss of 3c gene functionality [33–35], which has been 
associated with a loss of ability to replicate in enterocytes 
and therefore infectivity via the natural route [35, 36]. 
Enterocyte cell cultures have been used to more accu-
rately assess FCoV infectivity and virus copy number in a 
recent study [8]. However, use of enterocyte cell cultures 
was not possible in this study, nor was 3c gene sequenc-
ing attempted.
When calculating accuracy, the authors considered 
it very important to include samples for which S gene 
mutation analysis failed, as a more accurate reflection of 
the clinical situation where failure to identify the pres-
ence of mutated FCoVs may be considered lack of sup-
port of the diagnosis of FIP. We were not able to obtain 
pyrosequencing data in all samples; this was attributed to 
low relative FCoV copy number, failure of amplification 
primer binding, or failure of pyrosequencing primers to 
bind to viral cDNA as a result of sequence mismatches. 
Conventional sequencing of the pyrosequencing ampli-
con was possible in 21 cases in which pyrosequencing 
failed (n = 48 of 320 samples where pyrosequencing was 
attempted), significant secondary structure was predicted 
in these amplicons at the pyrosequencing primer binding 
site, which could account for the failure to pyrosequence 
[26]. Mixed non-mutated and mutated FCoV infections 
may also have been missed by the pyrosequencing assay 
as the amplification step biases the detected sequence 
towards the dominant virus type. In addition, both 
serotype 1 and serotype 2 FCoVs have been associated 
with the development of FIP; however, only mutations 
within the S protein fusion peptide of the more preva-
lent serotype 1 FCoVs have been associated with systemic 
infection and development of FIP [18, 20]. As the recom-
bination events that result in the formation of serotype 2 
FCoVs include the S protein gene, assays that characterise 
this portion of the genome are not applicable to serotype 
2 FCoVs. Therefore, it was predicted that pyrosequencing 
would fail for those samples containing serotype 2 FCoV; 
however, both serotype 1 and 2 FCoVs were detected by 
the RT-qPCR assay used in this study, as this assay tar-
gets a section of the genome not affected by the recom-
bination events [24]. In this study only cats that failed 
pyrosequencing were assessed for the presence of sero-
type 2 FCoVs, therefore it cannot be excluded that more 
cats had a dual infection with both serotypes. Spike gene 
mutation analysis, in combination with FCoV RT-qPCR, 
results in a modest increase in specificity, but this is offset 
by a decrease in sensitivity resulting in decreased accu-
racy. Independent of disease prevalence within a popula-
tion, there was no significant difference in the proportion 
of mutated FCoVs detected in tissue and body cavity fluid 
samples between cats with FIP and cats without FIP that 
were FCoV RT-qPCR-positive (χ2  =  2.96, p  =  0.086). 
Overall, the combination of FCoV RT-qPCR and S pro-
tein mutation analysis does not enhance the diagnosis 
of FIP over FCoV RT-qPCR alone, and S gene mutation 
analysis has significant time and cost implications.
It has been previously proposed that the M1058L or 
S1060A substitutions could affect the fusogenic activity 
and cell receptor specificity of the FCoV S protein [18, 
20], permitting entry into macrophages and monocytes. 
It is further proposed that additional FCoV mutations, 
along with changes within the host’s immunological 
response, are required to permit the seemingly uncon-
trolled replication seen during the development of FIP. 
These hypotheses are supported by the present study: 
firstly, the finding that the majority of FCoV detected in 
tissue samples from both cats with FIP and cats without 
FIP have M1058L or S1060A substitutions in the FCoV 
S protein; and secondly, as also described in a previ-
ous study of naturally infected cats [10], the finding that 
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FCoV RNA was detected in a far greater proportion 
of tissue samples from cats with FIP (90.4%) than tis-
sue samples from cats without FIP (7.8%), and, in those 
samples that were RT-qPCR positive, significantly higher 
FCoV relative copy numbers were found in the FIP sam-
ples (median 8.3 ×  103 vs. 25; U =  2161.5, p ≤  0.001). 
Other viral genomic mutations have also been associated 
with FIP, but were not evaluated as part of this study. For 
example, mutations in the S protein gene encoding amino 
acid differences in the furin cleavage motif [37] and the 
heptad HR1 region of the S2 subunit [38] have been cor-
related with disease. Truncations of the accessory pro-
tein 3c gene have also been associated with loss of ability 
to replicate within enterocytes and, as such, have only 
been reported in FIP-associated FCoVs [35]. However, 
characterisation of these viral genomic mutations was 
not within the aims of this study, and use of these viral 
genomic mutations in the diagnosis of FIP has, so far, not 
been suggested.
Other study limitations include lack of cytological 
data for fluid samples, which cannot be performed ret-
rospectively on stored samples, and was not consistently 
performed at the time of collection due to lack of clini-
cal justification in euthanased cats. However, a number 
of other studies have examined the use of immunocyto-
chemistry on fluid in the diagnosis of FIP [30, 39], and 
reported similar sensitivities for the diagnosis of FIP 
to the FCoV RT-qPCR used in this study, but observed 
increased false positive results resulting in reduced spe-
cificities. However, in our experience, false positive 
results are not a relevant issue, provided sufficient cell 
numbers can be examined; this can be achieved when 
cells are concentrated in cytospins or when fluids are 
used to prepare formalin-fixed, paraffin embedded cell 
pellets that can then be treated like a tissue specimen 
for IHC (unpublished observations; Anja Kipar) [5]. In 
addition, pyrosequencing was only used to target a small 
region of the serotype 1 FCoV genome.
The University of Bristol FIP Biobank cats included in 
this study represent a convenience population, includ-
ing cats for which FIP was not necessarily a differential 
diagnosis, and cats for which the samples available do not 
necessarily reflect clinical signs reported and, as such, 
clinically relevant samples of tissues essential for a defini-
tive diagnosis may not be included. Differences between 
the cats with FIP and cats without FIP in this conveni-
ence population are clearly demonstrated when age at 
diagnosis is compared, which reflects the diseases for 
which these cats were euthanased, with neoplasia being 
the most common reason for euthanasia in the signifi-
cantly older cats without FIP. This significant difference 
in the age could complicate comparison of faecal FCoV 
shedding between each clinical group (20% for non-
FIP vs. 64.6% for FIP group), as younger cats are more 
likely to have been recently exposed to factors that could 
increase likelihood of enteric FCoV infection such as 
multicat households (i.e. breeding cattery or rehoming 
shelter). One study found FCoV shedding was most com-
mon in young cats (90% in cats aged 8–56 weeks cf. 39% 
for cats > 56 weeks) [1]; however, another study of faecal 
FCoV shedding found no difference between different age 
categories (34.6%  <  1  year of age, 31.6% 1–5  years, and 
35.3% > 5 years) [40]. Ideally the cats without FIP would 
have been age and clinical sign matched to the cats with 
FIP; however, this was not possible and is generally very 
difficult to achieve in an unbiased clinical patient cohort. 
Previous case-controlled studies of FIP have either not 
reported age of either FIP or control cat populations [29, 
31, 41], or recruited healthy control cats [42]. One advan-
tage of the increased age in the cats without FIP is that 
it does imply that these cats would be unlikely to have 
gone on to develop FIP had their concurrent disease not 
resulted in euthanasia. The absence of clinically relevant 
samples of tissue for some cats resulted in their exclu-
sion from analysis, as a definitive diagnosis could not be 
achieved.
As in earlier studies using the same methodology [20, 
21], the present data suggest that the presence of M1058L 
or S1060A substitutions in the FCoV S protein are indica-
tive of systemic spread of FCoV and not a definitive 
marker of the development of FIP. Albeit less common 
than mutated FCoVs in cats with FIP, mutated FCoVs may 
be detected in cats without FIP, and non-mutated FCoVs 
may be detected in cats with FIP. Despite a slight increase 
in specificity of 92.6 to 94.6% for tissue samples, the addi-
tion of S gene mutation analysis to the detection of FCoV 
by RT-qPCR in samples from cats does not help in the 
differentiation of cats with and without FIP, and hence, 
does not aid in the clinical diagnosis of FIP.
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